Drug showdown: which pill tames cortisol better?

NCT ID NCT07268222

Recruiting now Disease control Sponsor: Laikο General Hospital, Athens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two medications, metyrapone and osilodrostat, in 150 adults with mild autonomous cortisol secretion (MACS). Participants receive one of the drugs, surgery, or watchful waiting. The goal is to see which drug better lowers cortisol and improves related health issues like high blood pressure and blood sugar over 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: metyrapone and osilodrostat (oral tablets)
What this could lead to: If successful, this trial could show which drug better controls cortisol levels and improves blood pressure, weight, and blood sugar in people with mild autonomous cortisol secretion.
What could go wrong: This is a relatively small Phase 4 trial, so results may not apply to everyone. Both drugs can cause side effects like nausea or low cortisol, and the study does not test a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC AUTONOMOUS CORTISOL SECRETION (MACS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ACTH-independent Cushing syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MILD AUTONOMOUS CORTISOL SECRETION (MACS)

Contacts and locations

Locations

Laikon General Hospital
RECRUITING

Athens, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.